固相生物科學公司收到STTR二期贈款項目的標題為:藥物發現鉛優化芯片的發展。他們獎資助在2009年美國複蘇與再投資法案和他們的項目將解決飼料複合鉛優化芯片的進一步發展和商業化(Multizyme芯片)高通量代鉛化合物的類似物加上細胞篩選生物活性的快速識別衍生品。這種能力直接影響藥物發現的一個關鍵瓶頸;即鉛化合物的高效優化與最優開發藥物藥理性質。固相生物科學公司提出把六個生物催化與生物活性化合物的藥理篩選提供快速識別特異性的目標,這是一個新的範例鉛優化。此外,Multizyme芯片平台將在相關行業,適合領導優化包括農用化學品、化妝品和藥妝品。固相技術將因此提高競爭力和效率的製藥、化妝品、化學工業,將作為豐富的新的和改進的商業產品。這項研究的廣泛影響是固相生物科學的進步將實現向創造更好、更安全的藥物,這些藥物降低開發成本,提高製藥行業的整體效率。固相將生成Multizyme芯片供製藥和生物技術公司,以促進他們的購買鉛優化程序,特別是那些涉及天然product-derived和複雜的合成小分子線索。低溫貯藏技術開發的第二階段將使芯片的銷售和chip-handling設備生產階段,並將允許固相技術平台的無縫滲透進入該公司的目標市場。 Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

NeuroGenomeX藥物發現公司發展新的大腦和神經係統疾病的治療。當前NeuroGenomeX發現程序集中在治療癲癇症和創傷性腦損傷的靶區。NeuroGenomeX推進其領導的候選藥物,2-deoxy-D-glucose (2 dg),作為一個抗驚厥的阻止癲癇發作和癲癇的有利影響與不利的長期後果。2 dg也已經顯示出良好的治療創傷性腦損傷的神經保護作用在動物模型(創傷性腦損傷)。

Allozyne是一種蛋白質優化公司致力於改善生物療法來治療的發展尚未被滿足的醫療需求的多個領域。Allozyne的兩個技術平台使氨基酸類似的公司,在任何指定的位置,到現有生物製劑導致改善療效、耐受性和藥理學。

百樂滿製藥公司是一個藥物研發公司專注於病態血管組件包括癌症、眼部疾病(黃斑變性和糖尿病性視網膜病變)、關節炎、纖維化疾病(肺纖維化)子宮內膜異位、骨質疏鬆症和皮膚疾病(牛皮癬和過敏性皮炎)。帕洛瑪擁有知識產權有關的一係列小分子藥物通過一個集成設計平台,定製和行業標準計算工具治療上述疾病的潛在治療。

Armgo製藥公司是一家生物製藥公司致力於發現和開發新型小分子療法治療虛弱的心髒,肌肉和神經紊亂。公司專有的藥物,稱為rycals,新類口服製劑,作用於一個新穎的治療目標,阿諾定受體/鈣釋放通道(RyR)位於肌質/細胞的內質網。Rycals采取行動穩定這些通道和修複泄漏由壓力引起的鈣與慢性疾病有關。這是假設RyR通道的泄漏,如果不及時治療,可能導致影響心髒疾病,骨骼肌和大腦。

薩爾茨堡療法是一個藥物開發公司發展Cytotoxamer Genotoxamer產品為癌症治療。該公司的技術旨在提供一個解決方案提供激活形式的抗癌藥物,納米粒子和其他專門半個癌細胞。